Close Menu

predictive technology

The grant will allow Weill Cornell to study genetic, social, and clinical factors that might explain why COVID-19 disproportionally affects minorities in the US.

The Oslo-based company plans to develop a test that can identify high-risk individuals based on an epigenetic signature.

Despite higher revenues, the bioinformatics company's net loss grew by 38 percent during the quarter due to rising expenses.

Backed by BARDA, Merck and Institute for Systems Biology are studying multiomic data to understand infection pathways and find biomarkers for symptom risk.

Although polygenic risk scores for coronary artery disease can slightly improve standard risk assessment tools, the predicted clinical impact remains small.

The companies are looking to model gene expression signatures to predict treatments for gastric cancer and improve patient stratification methodologies. 

Hitachi and Centre Léon Bérard have opened a research lab in Lyon that will apply AI to medical imaging and predict response to radiation therapy from genomic markers.

Researchers focused on using existing computational methods to fill in gaps in the human microbiome without reference genomes.

Bioinformaticians at the Free University of Brussels have built a database, machine learning technology, and web platform for identifying elusive pathogenic gene pairs.

The software, presented at the ISMB/ECCB conference, helps researchers fill in gaps in the human epigenome thanks to 3D deep-learning techniques.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.